55 completed, 9 recruiting, 8 terminated, 4 active not recruiting. 80 Phase 2, 17 Phase 1, 6 Phase 3.
Follow Pneumovirus Infections: new trials by email Literature Review of Pneumovirus Infections trials Research Report on Pneumovirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection. SYH2066, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 80 | 2026-11-13 | 2026-10-20 |
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus zelicapavir, Placebo - RSV Infection, RSV | Phase 2 | Recruiting | Enanta Pharmaceuticals, Inc | 150 | 2026-07-09 | 2026-07-20 |
| Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant) - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Recruiting | Ab&B Bio-tech Co., Ltd.JS | 470 | 2026-05-14 | 2026-05-27 |
| A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection. Ziresovir (AK0529), Placebo - Respiratory Syncytial Virus Infections | Phase 2 / Phase 3 | Recruiting | Shanghai Ark Biopharmaceutical Co., Ltd. | 290 | 2026-03-03 | 2026-06-22 |
| Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals Remdesivir, Survey Administration, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2025-12-23 | 2026-10-01 |
| A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease S-337395, Placebo - Respiratory Syncytial Virus Infections | Phase 2 | Recruiting | Shionogi | 192 | 2025-12-11 | 2026-10-21 |
| A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant - Respiratory Syncytial Virus Infection Prevention | Phase 2 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 700 | 2025-10-21 | 2026-02-11 |
| A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant Adjuvanted RSVPreF3 vaccine - Respiratory Syncytial Virus Infections | Phase 2 | Active not recruiting | GlaxoSmithKline | 168 | 2025-08-06 | 2026-09-28 |
| Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV Remdesivir - Respiratory Syncytial Virus (RSV) | Phase 2 | Recruiting | PENTA Foundation | 120 | 2025-07-16 | 2025-07-23 |
| Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults SCB-1019T, SCB-1022, SCB-1033 - RSV Infection, Human Metapneumovirus Infection | Phase 1 / Phase 2 | Active not recruiting | Clover Biopharmaceuticals AUS Pty | 612 | 2025-06-18 | 2026-10-26 |
| Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 4 | 2025-03-05 | 2026-06-08 |
| Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent) - Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization | Phase 1 / Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 1530 | 2024-11-11 | 2025-12-11 |
| Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 150 | 2024-10-14 | 2026-06-30 |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) Placebo comparator, PRS CK STORM - SARS-CoV-2, Influenza, Human | Phase 1 / Phase 2 | Recruiting | PEACHES BIOTECH | 50 | 2024-10-02 | 2026-06-10 |
| RSV Vaccination in Immunocompromised Patients. Arexvy powder and suspension for injection - RSV Infection | Phase 2 | Recruiting | Medical University of Vienna | 200 | 2024-09-19 | 2024-11-27 |
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults STR-V003/Placebo - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Unknown | Starna Therapeutics | 48 | 2024-05-01 | 2024-04-03 |
| Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older RSV vaccine candidate, Placebo - Respiratory Syncytial Virus Infection, Healthy Volunteers | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 4541 | 2024-04-02 | 2026-03-10 |
| A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV Deuremidevir Hydrobromide for Suspension, Placebo - Respiratory Syncytial Virus Infection | Phase 2 | Completed | Vigonvita Life Sciences | 60 | 2024-01-31 | 2025-07-23 |
| A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection Sisunatovir, Placebo - Respiratory Syncytial Virus Infection | Phase 2 / Phase 3 | Terminated | Pfizer | 16 | 2023-12-08 | 2025-11-10 |
| Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults RSV/Flu-01E, Placebo - Respiratory Synctial Virus Infections | Phase 2 | Completed | Research Institute of Influenza, Russia | 120 | 2023-12-07 | 2025-03-24 |
Showing 20 of 80. Sign in to see all of them.
Respiratory Syncytial Virus Infections (80) · Virus Diseases (3) · Infections (2) · Pneumonia (2) · Premature Birth (2) · Respiratory Tract Infections (2) · Autoimmune Diseases (1) · Bronchopulmonary Dysplasia (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Heart Defects, Congenital (1) · Heart Diseases (1) · Influenza, Human (1) · Lung Diseases (1) · Neoplasms (1)
Mononegavirales Infections (80) · RNA Virus Infections (80) · Paramyxoviridae Infections (79) · Infections (78) · Virus Diseases (77) · Respiratory Tract Diseases (5) · Cardiovascular Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Lung Diseases (2) · Obstetric Labor Complications (2) · Obstetric Labor, Premature (2) · Pregnancy Complications (2) · Urogenital Diseases (2) · Cardiovascular Abnormalities (1)
Saline Solution (5) · JNJ-53718678 (4) · ziresovir (4) · Palivizumab (3) · Respiratory Syncytial Virus Vaccines (3) · presatovir (3) · sisunatovir (3) · 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (2) · Boostrix (2) · EDP-938 (2) · Injections (2) · PC-786 (2) · Suspensions (2) · motavizumab (2) · remdesivir (2)
GlaxoSmithKline (12) · Enanta Pharmaceuticals, Inc (5) · Gilead Sciences (5) · Sanofi Pasteur, a Sanofi Company (5) · Shanghai Ark Biopharmaceutical Co., Ltd. (4) · Alnylam Pharmaceuticals (3) · Janssen Research & Development, LLC (3) · MedImmune LLC (3) · Pfizer (3) · Alios Biopharma Inc. (2) · AstraZeneca (2) · Bavarian Nordic (2) · Janssen Sciences Ireland UC (2) · Novavax (2) · Pulmocide Ltd (2)
United States (39) · United Kingdom (22) · Australia (17) · Spain (16) · Belgium (15) · Poland (14) · China (13) · Japan (13) · Canada (12) · France (12) · Italy (11) · South Africa (10) · South Korea (10) · Argentina (9) · Mexico (9)
Martin Zamora, MD (2) · Qin Yu (2) · Abbie Oey (1) · Adeyi Adeyemi, MD (1) · Akshay Vaishnaw, MD PhD (1) · Alan Glanville, MB BS MD Syd, FRACP (1)
PMID 29401325, PMID 31951765, PMID 38921800, PMID 20525274, PMID 20851929, PMID 22943074, PMID 25140957, PMID 26580997, PMID 28579233, PMID 29684148, PMID 31402384, PMID 31418022, PMID 31712214, PMID 31915807, PMID 32726422, PMID 32726528, PMID 33216113, PMID 34774184, PMID 35172056, PMID 35235733, PMID 35454123, PMID 35731653, PMID 35904987, PMID 36484484, PMID 36722147, PMID 37079393, PMID 37422079, PMID 37468530, PMID 37477875, PMID 37502622, PMID 37699064, PMID 38649595, PMID 38902186, PMID 39441691, PMID 40673795, PMID 40856556, PMID 40961446, PMID 41199924, PMID 42869044
2014 (5), 2016 (5), 2019 (4), 2018 (3), 2023 (3), 2017 (2), 2015 (1)